What is HC Wainwright’s Estimate for ACRV FY2024 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – HC Wainwright lowered their FY2024 EPS estimates for Acrivon Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.45) for the year, down from their prior estimate of ($2.31). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.45) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2024 earnings at ($0.61) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.23) EPS and FY2028 earnings at ($1.49) EPS.

Several other brokerages have also recently issued reports on ACRV. Piper Sandler Companies reiterated a “buy” rating and issued a $30.00 price target on shares of Acrivon Therapeutics in a research note on Friday, September 6th. LADENBURG THALM/SH SH raised Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and set a $17.00 target price on shares of Acrivon Therapeutics in a report on Monday, September 16th. Finally, BMO Capital Markets dropped their price target on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.67.

Acrivon Therapeutics Stock Down 9.9 %

Shares of NASDAQ:ACRV opened at $6.27 on Monday. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90. The company’s 50 day moving average price is $7.75 and its two-hundred day moving average price is $7.76. The firm has a market cap of $195.25 million, a PE ratio of -2.32 and a beta of 0.66.

Institutional Investors Weigh In On Acrivon Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC raised its stake in Acrivon Therapeutics by 78.2% during the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock worth $31,093,000 after acquiring an additional 2,353,000 shares in the last quarter. Sands Capital Ventures LLC grew its holdings in shares of Acrivon Therapeutics by 28.4% during the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock valued at $12,311,000 after purchasing an additional 470,000 shares during the last quarter. American International Group Inc. increased its position in Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after purchasing an additional 1,695 shares in the last quarter. Marshall Wace LLP increased its position in Acrivon Therapeutics by 58.8% during the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock worth $5,503,000 after purchasing an additional 351,397 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Acrivon Therapeutics by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock valued at $3,626,000 after purchasing an additional 31,208 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.